[1] |
Rovin BH, Ayoub IM, Chan TM, et al. Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus Nephritis[J]. Kidney Int, 2024, 105(1): 31-34.
doi: 10.1016/j.kint.2023.09.001
pmid: 38182299
|
[2] |
Kidney Disease: Improving Global Outcomes Lupus Nephritis Work G. KDIGO 2024 Clinical Practice Guideline for the management of LUPUS NEPHRITIS[J]. Kidney Int, 2024, 105(1S): S1-S69.
|
[3] |
高金旭, 王少侠, 茹晋丽. 儿童系统性红斑狼疮的生物制剂治疗现状与进展[J]. 中华风湿病学杂志, 2024, 28(8): 595-560.
|
|
Gao JX, Wang SX, Ru JL. The current status and progress of biologic therapy for children with systemic lupus erythematosus[J]. Zhonghua Fengshibingxue Zazhi, 2024, 28(8): 595-560.
|
[4] |
张宏文. 关于贝利尤单抗治疗儿童狼疮性肾炎的一些个人见解[J]. 临床儿科杂志, 2025, 43(2): 147-149.
|
|
Zhang HW. Some personal advices on belimumab treatment in childhood lupus nephritis[J]. Linchuang Erke Zazhi, 2025, 43(2): 147-149.
|
[5] |
Baskin E, Fidan K, Gulhan B, et al. Eculizumab treatment and discontinuation in pediatric patients with atypical hemolytic uremic syndrome: a multicentric retrospective study[J]. J Nephrol, 2022, 35(4): 1213-1222.
|
[6] |
Alhamoud I, Freiberg SA. Successful discontinuation of eculizumab in a pediatric patient with atypical hemolytic uremic syndrome and underlying systematic lupus erythematosus[J]. Cureus, 2022, 14(5): e25117.
|
[7] |
倪佳佳, 朱亚菊, 金晶, 等. 儿童系统性红斑狼疮合并血栓性微血管病的诊治与思考[J]. 临床儿科杂志, 2025, 43(2): 150-156.
|
|
Ni JJ, Zhu YJ, Jin J, et al. Diagnosis, treatment, and reflection on pediatric systemic lupus erythematosus complicated by thrombotic microangiopathy[J]. Linchuang Erke Zazhi, 2025, 43(2): 150-156.
|
[8] |
Thompson GL, Kavanagh D. Diagnosis and treatment of thrombotic microangiopathy[J]. Int J Lab Hematol, 2022, 44 Suppl 1(Suppl 1): 101-113.
|
[9] |
de Holanda MI, Porto LC, Wagner T, et al. Use of eculizumab in a systemic lupus erythemathosus patient presenting thrombotic microangiopathy and heterozygous deletion in CFHR1-CFHR3. A case report and systematic review[J]. Clin Rheumatol, 2017, 36(12): 2859-2867.
doi: 10.1007/s10067-017-3823-2
pmid: 28905254
|
[10] |
Lansigan F, Isufi I, Tagoe CE. Microangiopathic haemolytic anaemia resembling thrombotic thrombocytopenic purpura in systemic lupus erythematosus: the role of ADAMTS13[J]. Rheumatology (Oxford), 2011, 50(5): 824-829.
doi: 10.1093/rheumatology/keq395
pmid: 21149242
|
[11] |
Kim MJ, Lee H, Kim YH, et al. Eculizumab therapy on a patient with co-existent lupus nephritis and C3 mutation-related atypical haemolytic uremic syndrome: a case report[J]. BMC Nephrol, 2021, 22(1): 86.
doi: 10.1186/s12882-021-02293-2
pmid: 33691638
|
[12] |
Coppo R, Peruzzi L, Amore A, et al. Dramatic effects of eculizumab in a child with diffuse proliferative lupus nephritis resistant to conventional therapy[J]. Pediatr Nephrol, 2015, 30(1): 167-172.
doi: 10.1007/s00467-014-2944-y
pmid: 25173358
|
[13] |
El-Husseini A, Hannan S, Awad A, et al. Thrombotic microangiopathy in systemic lupus erythematosus: efficacy of eculizumab[J]. Am J Kidney Dis, 2015, 65(1): 127-130.
doi: 10.1053/j.ajkd.2014.07.031
pmid: 25446020
|
[14] |
Bermea RS, Sharma N, Cohen K, et al. Use of Eculizumab in Atypical Hemolytic Uremic Syndrome, Complicating Systemic Lupus Erythematosus[J]. J Clin Rheumatol, 2016, 22(6): 320-323.
doi: 10.1097/RHU.0000000000000423
pmid: 27556240
|
[15] |
Park MH, Caselman N, Ulmer S, et al. Complement-mediated thrombotic microangiopathy associated with lupus nephritis[J]. Blood Adv, 2018, 2(16): 2090-2094.
doi: 10.1182/bloodadvances.2018019596
pmid: 30131343
|
[16] |
Kello N, Khoury LE, Marder G, et al. Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: Case series and review of literature[J]. Semin Arthritis Rheum, 2019, 49(1): 74-83.
|
[17] |
Wright RD, Bannerman F, Beresford MW, et al. A systematic review of the role of eculizumab in systemic lupus erythematosus-associated thrombotic microangiopathy[J]. BMC Nephrol, 2020, 21(1): 245.
doi: 10.1186/s12882-020-01888-5
pmid: 32605540
|
[18] |
章玲霞, 王晶晶, 金艳艳, 等. 伊库珠单抗治疗儿童系统性红斑狼疮合并血栓性微血管病的2例经验分享及文献复习[J]. 中华肾脏病杂志, 2023, 39(12): 942-946.
doi: 10.3760/cma.j.cn441217-20230504-00502
|
|
Zhang LX, Wang JJ, Jin YY, et al. Eculizumab for treatment of thrombotic microangiopathy secondary to systemic lupus erythematosus in children: two cases report and literature review[J]. Zhonghua Shenzangbing Zazhi, 2023, 39(12): 942-946.
|
[19] |
殷蕾, 茅幼英, 周征宇, 等. 儿童系统性红斑狼疮并发血栓性微血管病的临床特点和早期识别[J]. 中国小儿急救医学, 2021, 28(10): 868-873.
|
|
Yin L, Mao YY, Zhou ZY, et al. Clinical characteristics and early recognition of thrombotic microangiopathy in children with systemic lupus erythematosus[J]. Zhongguo Xiaoer Jijiu Yixue, 2021, 28(10): 868-873.
|
[20] |
邹婵娟, 丁菱, 王敏, 等. 贝利尤单抗治疗系统性红斑狼疮合并血栓性微血管病1例并文献复习[J]. 中国医学前沿杂志 (电子版), 2023, 15(11): 71-78.
|
|
Zou CJ, Ding L, Wang M, et al. Belimumab in the treatment of systemic lupus erythematosus with thrombotic microangiopathy: a case report and literature review[J]. Zhongguo Yixue Qianyan Zazhi (Dianziban), 2023, 15(11): 71-78.
|
[21] |
李晓洁, 魏雅琴, 高春林, 等. 系统性红斑狼疮合并血栓性微血管病的病因及治疗[J]. 中华儿科杂志, 2023, 61(8): 753-756.
|
|
Li XJ, Wei YQ, Gao CL, et al. Pathogeny and treatment of systemic lupus erythematosus complicated with thrombotic microangiopathy[J]. Zhonghua Erke Zazhi, 2023, 61(8): 753-756.
|
[22] |
Loirat C, Fakhouri F, Ariceta G, et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children[J]. Pediatr Nephrol, 2016, 31(1): 15-39.
doi: 10.1007/s00467-015-3076-8
pmid: 25859752
|
[23] |
Bozio CH, Isenhour C, McNamara LA. Characteristics of and meningococcal disease prevention strategies for commercially insured persons receiving eculizumab in the United States[J]. PLoS One, 2020, 15(11): e0241989.
|